351 related articles for article (PubMed ID: 19059063)
1. Pharmacogenetics in pain management: the clinical need.
Webster LR
Clin Lab Med; 2008 Dec; 28(4):569-79. PubMed ID: 19059063
[TBL] [Abstract][Full Text] [Related]
2. Current evidence for a genetic modulation of the response to analgesics.
Lötsch J; Geisslinger G
Pain; 2006 Mar; 121(1-2):1-5. PubMed ID: 16472919
[No Abstract] [Full Text] [Related]
3. Pharmacogenetics and Personalized Medicine in Pain Management.
Webster LR; Belfer I
Clin Lab Med; 2016 Sep; 36(3):493-506. PubMed ID: 27514464
[TBL] [Abstract][Full Text] [Related]
4. Understanding the genetic determinants of pain and pain management.
Miaskowski C
Semin Oncol Nurs; 2009 May; 25(2 Suppl 1):S1-7. PubMed ID: 19447317
[TBL] [Abstract][Full Text] [Related]
5. [Genetic polymorphisms and human sensitivity to pain and opioids].
Nishizawa D; Nagashima M; Satoh Y; Tagami M; Ikeda K
Masui; 2009 Sep; 58(9):1093-101. PubMed ID: 19764431
[TBL] [Abstract][Full Text] [Related]
6. Genetic factors in pain and its treatment.
Stamer UM; Stüber F
Curr Opin Anaesthesiol; 2007 Oct; 20(5):478-84. PubMed ID: 17873601
[TBL] [Abstract][Full Text] [Related]
7. Pain and genetics.
Fernandez Robles CR; Degnan M; Candiotti KA
Curr Opin Anaesthesiol; 2012 Aug; 25(4):444-9. PubMed ID: 22732422
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics in palliative care.
Kleine-Brueggeney M; Musshoff F; Stuber F; Stamer UM
Forensic Sci Int; 2010 Dec; 203(1-3):63-70. PubMed ID: 20709477
[TBL] [Abstract][Full Text] [Related]
9. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.
Reynolds KK; Ramey-Hartung B; Jortani SA
Clin Lab Med; 2008 Dec; 28(4):581-98. PubMed ID: 19059064
[TBL] [Abstract][Full Text] [Related]
10. [Genetic polymorphisms and opioid therapies].
Landau R
Presse Med; 2008 Oct; 37(10):1415-22. PubMed ID: 18440763
[TBL] [Abstract][Full Text] [Related]
11. Are mu-opioid receptor polymorphisms important for clinical opioid therapy?
Lötsch J; Geisslinger G
Trends Mol Med; 2005 Feb; 11(2):82-9. PubMed ID: 15694871
[TBL] [Abstract][Full Text] [Related]
12. Can heterogeneity of chronic sickle-cell disease pain be explained by genomics? A literature review.
Adegbola MA
Biol Res Nurs; 2009 Jul; 11(1):81-97. PubMed ID: 19487302
[TBL] [Abstract][Full Text] [Related]
13. Effect of genetic factors on opioid action.
Kosarac B; Fox AA; Collard CD
Curr Opin Anaesthesiol; 2009 Aug; 22(4):476-82. PubMed ID: 19502975
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of opioids.
Somogyi AA; Barratt DT; Coller JK
Clin Pharmacol Ther; 2007 Mar; 81(3):429-44. PubMed ID: 17339873
[TBL] [Abstract][Full Text] [Related]
15. [Implication of genetic polymorphism on neuropathic pain].
Iseki M; Sato-Takeda M
Masui; 2009 Sep; 58(9):1112-21. PubMed ID: 19764434
[TBL] [Abstract][Full Text] [Related]
16. [Genetic variation-- important for the clinical effect of opioids?].
Klepstad P; Dale O; Borchgrevink PC; Kaasa S; Skorpen F
Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2655-8. PubMed ID: 16215614
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Crews KR; Monte AA; Huddart R; Caudle KE; Kharasch ED; Gaedigk A; Dunnenberger HM; Leeder JS; Callaghan JT; Samer CF; Klein TE; Haidar CE; Van Driest SL; Ruano G; Sangkuhl K; Cavallari LH; Müller DJ; Prows CA; Nagy M; Somogyi AA; Skaar TC
Clin Pharmacol Ther; 2021 Oct; 110(4):888-896. PubMed ID: 33387367
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of opioid pharmacogenetics.
Argoff CE
Clin J Pain; 2010 Jan; 26 Suppl 10():S16-20. PubMed ID: 20026961
[TBL] [Abstract][Full Text] [Related]
19. [Future pain treatment].
Rygh LJ; Fagerlund TH; Svendsen F
Tidsskr Nor Laegeforen; 2001 Jun; 121(16):1917-22. PubMed ID: 11488183
[TBL] [Abstract][Full Text] [Related]
20. Genetics and variability in opioid response.
Stamer UM; Bayerer B; Stüber F
Eur J Pain; 2005 Apr; 9(2):101-4. PubMed ID: 15737794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
